
Verimos Biotech Private Limited
Produces and sells bio fertilizer and bio pesticide, established in 2018 in Delhi.
Produces and sells bio fertilizer and bio pesticide, established in 2018 in Delhi.
Delhi, India
+91-XXXXXXXXXX
U01100DL2018PTC339187
339187
Private Limited Indian Non-Government Company
20 Sep 2018
25 Apr 2022
31 Mar 2022
Unlisted
Roc Delhi
Name | Designation | Appointment Date | Status |
---|---|---|---|
Ashok Prasad ![]() | Director | 20-Sep-2018 | Current |
Amit Sinha ![]() | Director | 01-Jun-2019 | Current |
Verimos Biotech Private Limited, for the financial year ended 2019, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth witnessed no change by increase of 0%.
Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
---|---|---|---|---|---|---|---|
Total Revenue | |||||||
Revenue from Operations | |||||||
Total Assets | |||||||
Profit or Loss | |||||||
Net Worth | |||||||
EBITDA |
In 2020, Verimos Biotech had a promoter holding of 99.00% and a public holding of 1.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Ashok Prasad and Amit Sinha are mutual person
Amit Sinha is a mutual person
Ashok Prasad and Amit Sinha are mutual person
There are no open charges registered against the company as per our records.
Unlock and access historical data on people associated with Verimos Biotech, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Gain comprehensive insights into the Deals and Valuation data of Verimos Biotech, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Verimos Biotech's trajectory.
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
Verimos Biotech Private Limited last Annual general meeting of members was held on 25 Apr 2022 as per latest MCA records.
Verimos Biotech Private Limited has filed its annual Financial statements for the year ended 31 Mar 2022 with Roc Delhi.
Amit Sinha was appointed as a Director was appointed as a Director on 01 Jun 2019 & has been associated with this company since 5 years 11 months .
Ashok Kumar Prasad was appointed as a Director was appointed as a Director on 20 Sep 2018 & has been associated with this company since 6 years 8 months .
Verimos Biotech Private Limited was registered on 20 Sep 2018 with Roc Delhi & aged 6 years 8 months as per MCA records.
Verimos Biotech Private Limited was incorporated on 20 Sep 2018.
The authorized share capital of Verimos Biotech Private Limited is ₹ 1.00 M and paid-up capital is ₹ 0.10 M.
Currently 2 directors are associated with Verimos Biotech Private Limited.
As per Ministry of Corporate Affairs (Mca), the registered address of Verimos Biotech Private Limited is 1852 Sector-B Pocket-1, Vasant Kunj India, New Delhi, 110070.
The corporate identification number (CIN) of Verimos Biotech Private Limited is U01100DL2018PTC339187 and the company number is 339187 as per Ministry of Corporate Affairs (MCA).
The most recent Balance Sheet for Verimos Biotech Private Limited was filed with the ROC on 31 Mar 2022.
Search company & director profiles for free and gain access to critical business data.
HG